HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)

The summary for the HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional): As part of NIHs Helping to End Addiction Long Term (HEAL) Initiative, this RFA invites research that will optimize multi-component service delivery interventions for people with opioid use disorder and co-occurring conditions, to include suicide risk. The purpose of the initiative is to support studies that will test (1) overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Studies are to be highly pragmatic and practice relevant, with designs that balance rigor with time-to-practice urgency. Projects will seek to a) identify constitute components that drive improvements in access, continuity, quality, value, and outcomes of care, for service delivery interventions with previously demonstrated effectiveness as a bundled package; and b) simultaneously test overall effectiveness of the package and its subcomponents, for popular (widely implemented) service delivery packages without previously demonstrated effectiveness.

Federal Grant Title:	HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-21-145
Type of Funding:	Grant
CFDA Numbers:	93.213, 93.242, 93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 18th, 2021
Original Application Deadline:	March 18th, 2021
Posted Date:	January 11th, 2021
Creation Date:	January 11th, 2021
Archive Date:	April 23rd, 2021
Total Program Funding:
Maximum Federal Grant Award:	$2,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 11th, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-145.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...; • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required); • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...; • Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01...; • Probiotics for Pediatric Illnesses; • Cam Practitioner Research Education Project Grant Partnership; • Complementary and Alternative Medicine Career Transition Award (K22)
More Grants from the National Institutes of Health: • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)